Table 2.
Median serum levels of RANKL, OPG, and RANKL/OPG ratio in all groups.
| Analyte (pg/mL) | Normal BMD (N; n = 25) |
Low BMD (L; n = 46) |
P (N vs L) | Osteopenia (OSN; n = 31) |
P (N vs OSN) | Osteoporosis (OSR; n = 15) |
P (N vs OSR) | P (OSN vs OSR) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |||||
| RANKL | 42.4 | 29.7 | 42.7 | 57.9 | .721 | 42.7 | 65.0 | .974 | 34.0 | 36.5 | .445 | .606 |
| OPG | 563.3 | 273.1 | 468.0 | 136.4 | .004 | 471.3 | 133.1 | .008 | 466.5 | 164.6 | .025 | .634 |
| RANKL/OPG ratio | 0.079 | 0.06 | 0.1 | 0.13 | .027 | 0.1 | 0.17 | .026 | 0.88 | 0.12 | .19 | .699 |
BMD, bone mineral density; IQR, intraquartile range; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor κB ligand.
Significant P-values are depicted in bold.